Crescendo Bioscience is Conducting a Study to Evaluate Patient Outcomes
The Crescendo Bioscience Outcome Study compares Vectra DA guided-care to usual care for rheumatoid arthritis (RA) patients with inadequate response to methotrexate.
To qualify for this study, you must:
• Be between the ages of 18 and 80 years old
• Have received weekly methotrexate (MTX) treatment for at least 3 months
• Have at least 3 swollen and 3 tender joints
• Additional criteria may apply
How do I learn more about the RA Study?
If you are interested in the Outcome Study, you must meet the study criteria and a participating rheumatologist must enroll you. There are currently 40 participating rheumatologists in 22 states, and up to 60 participating rheumatologists in the coming months.
For more information, please see the U.S. National Institutes of Health webpage.
Click one of the pins below for more information on a provider near you!